To be cost-effective, Biogen should slash Spinraza price, and Novartis cannot justify a $4M-$5M price tag for Zolgensma — ICER
As treatments for rare diseases and gene therapies make strides on the US market, the issue of pricing is once again center stage. Biogen should cut the price of its spinal muscular atrophy (SMA) treatment Spinraza and the price for Novartis’ one-shot Zolgensma — which is expected to win FDA approval by May — is justifiable up to $1.5 million, Boston-based ICER concluded on Wednesday.
Akin to NICE in the UK, ICER is an independent body that analyzes the cost-effectiveness of drugs and other medical services in the United States. Unlike NICE, though, ICER is not government-affiliated, but its determinations are increasingly becoming influential with payers.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.